Literature DB >> 3312285

Detection of Pneumocystis carinii by fluorescent-antibody stain using a combination of three monoclonal antibodies.

V J Gill1, G Evans, F Stock, J E Parrillo, H Masur, J A Kovacs.   

Abstract

A combination of three monoclonal antibodies, two prepared against human and one against rat Pneumocystis carinii, was used in an indirect fluorescent-antibody stain (IFA) to diagnose P. carinii in both bronchoalveolar lavage and lung biopsy specimens. This combination of monoclonal antibodies was specific for P. carinii and yielded bright fluorescence of both P. carinii cysts and trophozoites. A total of 126 specimens from 93 patients were stained for P. carinii by a toluidine blue O stain and the monoclonal IFA. Forty-five (35.7%) of these were positive for P. carinii by toluidine blue O, and 43 (34.1%) were positive by IFA. There was 98.4% agreement between both methods, with no false-positive and two false-negative occurrences by IFA. An IFA procedure with monoclonal antibodies such as those used in these studies can provide a simple, fast, and sensitive method for diagnosing P. carinii pneumonia by microbiology laboratories.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312285      PMCID: PMC269351          DOI: 10.1128/jcm.25.10.1837-1840.1987

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Preparation of monoclonal antibodies: strategies and procedures.

Authors:  G Galfrè; C Milstein
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

2.  Studies of morphology and immunofluorescence of Pneumocystis carinii.

Authors:  H K Kim; W T Hughes; S Feldman
Journal:  Proc Soc Exp Biol Med       Date:  1972-10

3.  Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections in the acquired immunodeficiency syndrome.

Authors:  C Broaddus; M D Dake; M S Stulbarg; W Blumenfeld; W K Hadley; J A Golden; P C Hopewell
Journal:  Ann Intern Med       Date:  1985-06       Impact factor: 25.391

4.  Bronchoalveolar lavage as the exclusive diagnostic modality for Pneumocystis carinii pneumonia. A prospective study among patients with acquired immunodeficiency syndrome.

Authors:  J A Golden; H Hollander; M S Stulbarg; G Gamsu
Journal:  Chest       Date:  1986-07       Impact factor: 9.410

5.  Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host.

Authors:  D E Stover; M B Zaman; S I Hajdu; M Lange; J Gold; D Armstrong
Journal:  Ann Intern Med       Date:  1984-07       Impact factor: 25.391

6.  The diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome using subsegmental bronchoalveolar lavage.

Authors:  F P Ognibene; J Shelhamer; V Gill; A M Macher; D Loew; M M Parker; E Gelmann; A S Fauci; J E Parrillo; H Masur
Journal:  Am Rev Respir Dis       Date:  1984-06

Review 7.  Pneumocystis carinii and Toxoplasma gondii infections in patients with AIDS.

Authors:  J Mills
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

8.  The morphologic identification of Pneumocystis carinii.

Authors:  R L Pintozzi; L J Blecka; S Nanos
Journal:  Acta Cytol       Date:  1979 Jan-Feb       Impact factor: 2.319

9.  Advantages of a modified toluidine blue O stain and bronchoalveolar lavage for the diagnosis of Pneumocystis carinii pneumonia.

Authors:  L L Gosey; R M Howard; F G Witebsky; F P Ognibene; T C Wu; V J Gill; J D MacLowry
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

10.  Prospective evaluation of a monoclonal antibody in diagnosis of Pneumocystis carinii pneumonia.

Authors:  J A Kovacs; V Gill; J C Swan; F Ognibene; J Shelhamer; J E Parrillo; H Masur
Journal:  Lancet       Date:  1986-07-05       Impact factor: 79.321

  10 in total
  24 in total

Review 1.  Extrapulmonary pneumocystosis.

Authors:  V L Ng; D M Yajko; W K Hadley
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  Laboratory investigation of Pneumocystis carinii pneumonia.

Authors:  J M Chatterton; D O Yen
Journal:  Genitourin Med       Date:  1992-10

3.  Improved detection of Pneumocystis carinii by an immunofluorescence technique using monoclonal antibodies.

Authors:  M Orholm; W Holten-Andersen; J D Lundgren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

4.  Monoclonal immunofluorescence compared with silver stain for investigating Pneumocystis carinii pneumonia.

Authors:  J Midgley; P A Parsons; D C Shanson; O A Husain; N Francis
Journal:  J Clin Pathol       Date:  1991-01       Impact factor: 3.411

Review 5.  Pneumocystis carinii, an opportunist in immunocompromised patients.

Authors:  M S Bartlett; J W Smith
Journal:  Clin Microbiol Rev       Date:  1991-04       Impact factor: 26.132

6.  Application and staining patterns of commercial anti-Pneumocystis carinii monoclonal antibodies.

Authors:  K Elvin; E Linder
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

Review 7.  Why have Pneumocystis carinii trophozoites been ignored?

Authors:  J M Chatterton; A W Joss; M M Davidson; D O Ho-Yen
Journal:  J Clin Pathol       Date:  1990-04       Impact factor: 3.411

8.  Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia.

Authors:  Hans Henrik Larsen; Henry Masur; Joseph A Kovacs; Vee J Gill; Victoria A Silcott; Palaniandy Kogulan; Janine Maenza; Margo Smith; Daniel R Lucey; Steven H Fischer
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

9.  Optimal use of the cytocentrifuge for recovery and diagnosis of Pneumocystis carinii in bronchoalveolar lavage and sputum specimens.

Authors:  V J Gill; N A Nelson; F Stock; G Evans
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

10.  Detection of Pneumocystis carinii with direct fluorescence antibody and calcofluor white stain.

Authors:  J Aslanzadeh; P S Stelmach
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.